# Pliant Therapeutics Inc. (PLRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $1.16 (-2.52%)

> Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies. The company leverages integrin receptor biology to create novel small-molecule inhibitors and monoclonal antibodies that modulate key pathways like TGF-β signaling, aiming for tissue-specific targeting to address unmet needs in these areas. Its pipeline features bexotegrast, an oral dual selective inhibitor of αvβ6 and αvβ1 integrins, previously advanced for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; PLN-101095, an oral dual inhibitor of αvβ8 and αvβ1 integrins under evaluation in Phase 1 trials for advanced solid tumors resistant to immune checkpoint inhibitors, both as monotherapy and with pembrolizumab; and PLN-101325, a monoclonal antibody agonist of α7β1 integrin with regulatory clearance for Phase 1 studies in muscular dystrophies. Pliant Therapeutics Inc. maintains a proprietary discovery platform with integrin-binding molecules and screening assays to support tissue-specific drug delivery across multiple indications. Incorporated in 2015 and headquartered in South San Francisco, California, the company plays a significant role in advancing precision therapies within the biotechnology sector.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/PLRX)